Value through Innovation02 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next
07.12.2011

Winners of the Making More Health Competition Bring Fresh Innovation to Solving Problems in Health

01.12.2011

Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab

23.11.2011

Pradaxa® awarded Prix Galien for most innovative product in Canada

- For NON-US, Non-Canada and NON-UK Healthcare Media Only
17.11.2011

Boehringer Ingelheim race to the finish line in support of World Diabetes Day

- EX US and UK.
14.11.2011

New RE-LY® sub-analyses demonstrate safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with heart failure & those undergoing surgery

- For NON-US, NON-Canada and NON-UK Healthcare Media Only
09.11.2011

Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition

08.11.2011

BI 201335 demonstrates potential to shorten HCV treatment duration while achieving high sustained virological response rates in difficult to treat patients

- For media outside of the U.S.A only
07.11.2011

Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve a virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

- For media outside of the U.S.A. only
04.11.2011

Boehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® in acute ischaemic stroke for majority of EU countries*

- For non-UK and non-US media
01.11.2011

NICE issues Final Appraisal Determination (FAD) with unrestricted recommendation for Pradaxa® (dabigatran etexilate) for patients with non-valvular atrial fibrillation

- For NON-US, UK & Canada Media Only
27.10.2011

Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe

- For European Health Media Only
06.10.2011

Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors

27.09.2011

BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events

- FOR NON-US MEDIA ONLY
27.09.2011

European Respiratory Society (ERS) Awards Annual COPD Research Prize

26.09.2011

Boehringer Ingelheim expands its Business with Biosimilars

22.09.2011

New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis

- For NON-U.S Health Media Only
21.09.2011

Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives approval in the EU

- For non-US healthcare media
21.09.2011

Boehringer Ingelheim enrols first patient in Phase III program for new once-daily fixed-dose combination of tiotropium plus olodaterol in COPD

- For Media outside the U.S. and Canada
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 next